Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications. These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.
An Aryl Hydrocarbon (AHR) null rat model has been generated with the CRISPR/Cas9 editing system. The rat model may be used to study how exposure to environmental pollutants (especially dioxins), acting through AHR, shapes placental development.
A novel anti-metastasis therapy for prostate cancer, utilizing the newly established small-activating RNA (saRNA) technique to up-regulate the expression of the tumor metastasis suppressor gene, dihydropyrimidase-like 3 (DPYSL3).